RS104504A - Novi trombomodulin fuzioni proteini koji ciljaju tkivni faktor kao aktikoagulanti - Google Patents

Novi trombomodulin fuzioni proteini koji ciljaju tkivni faktor kao aktikoagulanti

Info

Publication number
RS104504A
RS104504A YUP-1045/04A YUP104504A RS104504A RS 104504 A RS104504 A RS 104504A YU P104504 A YUP104504 A YU P104504A RS 104504 A RS104504 A RS 104504A
Authority
RS
Serbia
Prior art keywords
domain
tissue factor
fusion proteins
anticoagulants
thrombomodulin
Prior art date
Application number
YUP-1045/04A
Other languages
English (en)
Inventor
David Light
Kirk Mc Lean
Original Assignee
Schering Aktiengesellschaft,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS104504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft, filed Critical Schering Aktiengesellschaft,
Publication of RS104504A publication Critical patent/RS104504A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na nove fuzione proteine koji se sastoje od proteina za ciljanje koji vezuje tkivo faktor (TF), koji je operativno vezan za trombomodulin (TM) EGF456 domen sam ili u kombinaciji sa bar još jednim TM domenom odabranom od grupe koja se sastoji od N-krajnjeg hidrofobicnog region domena, EGF 123 domena, interdomen obruča izmedju EGF3 i EGF4, i O-glikozilovanog Ser/Thr-bogatog domena, ili njihovih analoga, fragmenta, derivata i varijanti. Fuzioni protein se vezuje na položaju povrede i sprečava iniciranje tromboze. Fuzioni protein može biti upotrebljen da tretira različita tromboticna stanja uključujući ali ne limitirajuci na duboku vensku trombozu, raširenu intravaskularnu koagulaciju, i akutni koronarni sindrom.
YUP-1045/04A 2002-05-01 2003-04-30 Novi trombomodulin fuzioni proteini koji ciljaju tkivni faktor kao aktikoagulanti RS104504A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013522 WO2003092602A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants

Publications (1)

Publication Number Publication Date
RS104504A true RS104504A (sr) 2007-02-05

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
YUP-1045/04A RS104504A (sr) 2002-05-01 2003-04-30 Novi trombomodulin fuzioni proteini koji ciljaju tkivni faktor kao aktikoagulanti
YU102404A RS102404A (sr) 2002-05-01 2003-04-30 Nova antitela koja ciljaju tkivni faktor kao antikoagulanti

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU102404A RS102404A (sr) 2002-05-01 2003-04-30 Nova antitela koja ciljaju tkivni faktor kao antikoagulanti

Country Status (29)

Country Link
US (3) US7250168B2 (sr)
EP (2) EP1503785B1 (sr)
JP (2) JP4460443B2 (sr)
KR (2) KR101013697B1 (sr)
CN (2) CN100412090C (sr)
AR (1) AR039515A1 (sr)
AT (2) ATE427121T1 (sr)
AU (2) AU2003225256B2 (sr)
BR (2) BR0304660A (sr)
CA (2) CA2483909A1 (sr)
CR (1) CR7584A (sr)
DE (2) DE60334538D1 (sr)
DK (2) DK1549341T3 (sr)
EC (2) ECSP045467A (sr)
ES (2) ES2323056T3 (sr)
HK (1) HK1080372A1 (sr)
IL (3) IL164733A0 (sr)
MX (2) MXPA04010795A (sr)
NO (2) NO20035848L (sr)
NZ (2) NZ536242A (sr)
PE (1) PE20040597A1 (sr)
PL (2) PL373945A1 (sr)
PT (2) PT1503785E (sr)
RS (2) RS104504A (sr)
RU (2) RU2345789C2 (sr)
TW (1) TWI343388B (sr)
UA (2) UA85996C2 (sr)
WO (2) WO2003092602A2 (sr)
ZA (2) ZA200409692B (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1188830T3 (da) 1999-06-02 2010-04-26 Chugai Pharmaceutical Co Ltd Nyt hæmopoietinreceptorprotein NR10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
EP2325337A1 (en) 2000-09-26 2011-05-25 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
JP4460443B2 (ja) * 2002-05-01 2010-05-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化された抗体
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
CN1980947B (zh) 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
CN101189334B (zh) 2005-06-03 2013-11-06 持田制药株式会社 抗cd14抗体融合蛋白质
US20090130104A1 (en) * 2005-10-05 2009-05-21 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
ES2353084T3 (es) * 2006-04-07 2011-02-25 Novo Nordisk Health Care Ag Complejo covalente de factor vii y factor tisular.
CA2654623C (en) 2006-06-08 2016-07-26 Chugai Seiyaku Kabushiki Kaisha An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
KR20090051777A (ko) * 2006-10-06 2009-05-22 아사히 가세이 파마 가부시키가이샤 파종성 혈관내 혈액 응고 증후군의 치료 및/또는 개선제
US9649499B2 (en) * 2007-03-28 2017-05-16 Medtronic ATS Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
CN101855243A (zh) * 2007-09-20 2010-10-06 伯拉考成像股份公司 用于制备新的寡克隆抗体的方法
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
MX2011001696A (es) * 2008-08-14 2011-03-25 Merck Sharp & Dohme Metodos para purificar anticuerpos usando cromatografia de afinidad con proteina a.
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
US20120178693A1 (en) * 2009-08-28 2012-07-12 Bayer Healthcare Llc Cofactors for Thrombin Activation of Factor VII and Uses Thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
ES2676874T3 (es) 2010-06-04 2018-07-25 Tiumbio Co., Ltd. Proteína de fusión que tiene actividad del factor VII
NZ604718A (en) 2010-06-15 2015-01-30 Genmab As Human antibody drug conjugates against tissue factor
JP6234224B2 (ja) * 2010-08-05 2017-11-22 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 血栓溶解及び抗凝固特性を有するタンパク質融合構築物
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
CN107614016B (zh) 2015-04-14 2022-06-17 中外制药株式会社 包含il-31拮抗剂作为活性成分的用于预防和/或治疗特应性皮炎的药物组合物
US10954502B2 (en) * 2015-04-28 2021-03-23 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein C activators
WO2017189943A1 (en) * 2016-04-28 2017-11-02 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
PE20190966A1 (es) * 2016-11-16 2019-07-08 Bayer Healthcare Llc Factor viii direccionado a los globulos rojos y metodo para su uso
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
EP3861127A1 (en) * 2018-10-04 2021-08-11 Thrombosis and Coagulation AB Method for the determination of protein s levels
KR102416078B1 (ko) 2019-11-20 2022-07-01 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) * 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
JPH04505554A (ja) * 1989-02-17 1992-10-01 コドン 可溶性トロンボモジュリン類似体
US5466668A (en) * 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
KR930008093B1 (ko) * 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) * 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP3998419B2 (ja) * 1998-04-03 2007-10-24 中外製薬株式会社 ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
CA2402596A1 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) * 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003057911A2 (en) 2002-01-08 2003-07-17 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
JP4460443B2 (ja) * 2002-05-01 2010-05-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化された抗体
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
UA81114C2 (en) 2007-12-10
DK1549341T3 (da) 2009-07-06
US20040063632A1 (en) 2004-04-01
JP4460443B2 (ja) 2010-05-12
WO2003093422A3 (en) 2004-07-15
BR0304660A (pt) 2005-06-07
KR20050045944A (ko) 2005-05-17
KR101013697B1 (ko) 2011-02-10
DE60326970D1 (de) 2009-05-14
ES2354419T3 (es) 2011-03-14
US20080020965A1 (en) 2008-01-24
CN1665534A (zh) 2005-09-07
NO20035849L (no) 2004-02-27
WO2003092602A3 (en) 2004-08-26
EP1503785B1 (en) 2010-10-13
CA2483909A1 (en) 2003-11-13
NZ536243A (en) 2006-06-30
US20080019985A1 (en) 2008-01-24
UA85996C2 (ru) 2009-03-25
IL164733A0 (en) 2005-12-18
JP2005538046A (ja) 2005-12-15
CN100412090C (zh) 2008-08-20
TWI343388B (en) 2011-06-11
AU2003225256B2 (en) 2009-06-04
KR101080587B1 (ko) 2011-11-04
IL164732A0 (en) 2005-12-18
ECSP045467A (es) 2005-01-28
AU2003225255B2 (en) 2008-07-31
ES2323056T3 (es) 2009-07-06
US7622457B2 (en) 2009-11-24
EP1549341B1 (en) 2009-04-01
CN100563709C (zh) 2009-12-02
JP4567437B2 (ja) 2010-10-20
CR7584A (es) 2006-05-30
RU2004135306A (ru) 2005-07-10
CN1665526A (zh) 2005-09-07
DK1503785T3 (da) 2011-02-07
NZ536242A (en) 2006-04-28
US7250168B2 (en) 2007-07-31
RU2320366C2 (ru) 2008-03-27
ATE427121T1 (de) 2009-04-15
EP1549341A2 (en) 2005-07-06
PT1503785E (pt) 2011-01-17
BR0304659A (pt) 2004-09-21
PT1549341E (pt) 2009-05-29
EP1549341A4 (en) 2006-10-18
WO2003092602A2 (en) 2003-11-13
PL373945A1 (en) 2005-09-19
RS102404A (sr) 2006-12-15
ATE484524T1 (de) 2010-10-15
MXPA04010851A (es) 2005-02-14
PE20040597A1 (es) 2004-10-06
PL373960A1 (en) 2005-09-19
HK1080372A1 (zh) 2006-04-28
RU2004135308A (ru) 2005-08-10
CA2483910A1 (en) 2003-11-13
EP1503785A2 (en) 2005-02-09
RU2345789C2 (ru) 2009-02-10
EP1503785A4 (en) 2007-02-14
WO2003093422A2 (en) 2003-11-13
JP2005532045A (ja) 2005-10-27
AU2003225255A1 (en) 2003-11-17
NO20035848L (no) 2004-02-27
DE60334538D1 (de) 2010-11-25
ZA200409694B (en) 2006-02-22
ZA200409692B (en) 2006-07-26
AU2003225256A1 (en) 2003-11-17
PL210582B1 (pl) 2012-02-29
TW200307043A (en) 2003-12-01
IL164733A (en) 2011-05-31
MXPA04010795A (es) 2005-03-07
KR20050045945A (ko) 2005-05-17
US7622122B2 (en) 2009-11-24
ECSP045468A (es) 2005-01-28
AR039515A1 (es) 2005-02-23

Similar Documents

Publication Publication Date Title
UA85996C2 (ru) Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору
DE69225426D1 (de) Neue Thrombin-Inhibitoren
DE60238782D1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
PT1187918E (pt) Antagonistas de tek
WO2002083849A3 (en) Vascular endothelial growth factor 2
EP1385864A4 (en) GROWTH FACTOR 2, ENDOTHELIAL, VASCULAR
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
NO20033839L (no) Transplantatrejeksjonssuppressorer
ATE451842T1 (de) Proteingelbildung
ATE540976T1 (de) Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
WO2006119035A3 (en) Vegf variants
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
DE60236212D1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
WO2003000183A3 (en) Method of treating atherosclerosis and other inflammatory diseases
WO2004073649A3 (en) Clk-peptide and slk-peptide
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
EP1808179A3 (en) Use of HSP20 for promoting wound healing and/or reducing scar formation
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
WO2003092669A3 (en) Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
EA199800819A1 (ru) Способ лечения биполярного расстройства
DE50200864D1 (de) Verbundelemente enthaltend bitumen
Müller et al. 220 Characterization of human plasma fibrinogen molecular-size-variants by HPLC and amino acid sequence analysis